Search
Oxycodone
go.drugbank.com/drugs/DB00497ApprovedIllicitInvestigational[A178696] It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics … [Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.[L6460]
Mixtures: TARGIN 10MG/5MG, TARGIN 10MG/5MGProducts: Oxycontin 10mg, CARENOXAL 10MGNintedanib
go.drugbank.com/drugs/DB09079ApprovedInvestigational[L8453,L8459] It was first approved for use in the United States in 2014. … such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function.
Products: OFEV SOFT CAPSULES 100MG, OFEV SOFT CAPSULES 150MGLamotrigine
go.drugbank.com/drugs/DB00555ApprovedInvestigationalIt is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. … [A191350] Lamotrigine has relatively few side-effects and does not require laboratory monitoring.
Products: IPCALAM® 100MG, LAMITOR 100MG TABLETCarboplatin
go.drugbank.com/drugs/DB00958ApprovedInvestigational[A230523] Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248]
Products: Neoplatin Inj 10mg/ml, Paraplatin-AQ Inj 10mg/mlButylscopolamine
go.drugbank.com/drugs/DB09300ApprovedInvestigationalVet approvedButylscopolamine is a peripherally acting antimuscarinic, anticholinergic agent. It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic activity in the digestive system. It is also effect...
Mixtures: ACETAMINOFEN 325 MG + N-BUTILBROMURO DE HIOSCINA 10MG TABLETAS, ACETAMINOFEN 325 MG + N-BUTILBROMURO DE HIOSCINA 10MG TABLETASProducts: BS RATIOPHARM 20MG/ML ILO, Uscine Tablets 10mgEntrectinib
go.drugbank.com/drugs/DB11986ApprovedInvestigational[L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. … This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.[A183929]
Products: ROZLYTREK HARD CAPSULE 100MG, ROZLYTREK CÁPSULAS DURAS 100MGCanagliflozin
go.drugbank.com/drugs/DB08907ApprovedInvestigationalCanagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise … It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type
Mixtures: Vokanamet (Canagliflozin 150mg/ Metformin 1000mg) Film-Coated Tablet, VOKANAMET TM TABLETAS RECUBIERTAS 50 / 1000MGProducts: Invokana 100mg Film-Coated Tablets, Invokana 300mg Film-Coated TabletsPentobarbital
go.drugbank.com/drugs/DB00312ApprovedVet approvedA short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally.
Products: Novo-pentobarb 100mg, Nembutal Sodium Cap 100mgMethoxy polyethylene glycol-epoetin beta
go.drugbank.com/drugs/DB09107ApprovedInvestigationalMethoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent (ESA) with a longer half-life than erythropoietin. ESA is used to increase synthesis of red blood cells to treat chronic kidney disease...
Products: MIRCERA 100UG/0.3ML, MIRCERA 100UG 0.3MLAsunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawnAsunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor. … [A32528] It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.[L1113]
Products: SUNVEPRA CAPSULE 100MG, SUNVEPRA® 100MG CÁPSULAS BLANDAS